February 2019 FDA Recall Drug by Mylan Pharmaceuticals Inc.
D-0506-2019 - Failed Impurities/Degradation Specifications

This Class III drug recall was voluntarily initiated by Mylan Pharmaceuticals Inc. on February 13, 2019 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed in Throughout the United States and the recall is currently terminated.

Recall Number: D-0506-2019

Reason for Recall
Failed Impurities/Degradation Specifications: High out of specification results obtained during routine stability testing
Initiated
02-13-2019
Reported
02-27-2019
Quantity
8,159 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Mylan Pharmaceuticals Inc.
Throughout the United States
Diltiazem HCl Extended-Release Capsules, USP 180mg, Packaged in a) 100-count bottles (NDC 0378-5280-01), and b) 500-count bottles (NDC 0378-5280-05), Rx only, Manufactured by: Mylan Pharmaceuticals Inc. Morgantown, WV, 26505

Batch or Lot Expiration Information

Lot# : 3090167, Exp. October 2019